HAEMONETICS CORPORATION (NYSE:HAE) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
HAEMONETICS CORPORATION (NYSE:HAE) Files An 8-K Regulation FD Disclosure
On July 22, 2019, Haemonetics Corporation (the \”Company\”) issued a press release announcing changes to its financial reporting segments and business units that correspond with the Company\’s transition to a customer-centric business unit structure. The Company will report results in three segments: Plasma, Hospital and Blood Center. In connection with this announcement, the Company has posted to the Investor Relations page on its website (www.haemonetics.com) a presentation describing the reporting changes, analytical tables with two years of historical revenue information in the new segment structure and, for illustrative purposes, its fiscal year 2020 revenue guidance issued on May 14, 2019 in the new customer-centric business unit structure.
A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
HAEMONETICS CORP Exhibit
EX-99.1 2 exhibit991-pressrelease722.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 News Release Investor Contacts Media ContactGerry Gould,…
To view the full exhibit click
EX-99.1 2 exhibit991-pressrelease722.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 News Release Investor Contacts Media ContactGerry Gould,…
To view the full exhibit click
hereAbout HAEMONETICS CORPORATION (NYSE:HAE)
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.
